Evidence map›Paper›PMID 26070608›Full record

ArticleDiagnostic pathology2015

Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.

Patrice Desmeules, Hélène Hovington, Molière Nguilé-Makao, Caroline Léger, André Caron, Louis Lacombe, Yves Fradet, Bernard Têtu, Vincent Fradet

Open access · goldAbstract readComparative Study
In one paragraph

Article in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Can we use Ki67 expression to predict prostate cancer aggressiveness?Revista do Colegio Brasileiro de Cirurgioes · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Patrice DesmeulesCancer Research Centre, CHU de Québec, Québec, Canada. patrice.desmeules.1@ulaval.ca.
Hélène HovingtonDepartment of Surgery/Urology, Faculty of Medicine, Laval University, Québec, Canada. Helene.Hovington@crchudequebec.ulaval.ca.
Molière Nguilé-MakaoDepartment of Surgery/Urology, Faculty of Medicine, Laval University, Québec, Canada. moliere.nguile@gmail.com.
Caroline LégerDepartment of Surgery/Urology, Faculty of Medicine, Laval University, Québec, Canada. caroline.leger@crchudequebec.ulaval.ca.
André CaronDepartment of Medicine, Faculty of Medicine, University of Montreal, Montreal, Canada. Andre.Caron@crchudequebec.ulaval.ca.
Louis LacombeDepartment of Surgery/Urology, Faculty of Medicine, Laval University, Québec, Canada. Louis.Lacombe@crchudequebec.ulaval.ca.
Yves FradetDepartment of Surgery/Urology, Faculty of Medicine, Laval University, Québec, Canada. yves.fradet@crchudequebec.ulaval.ca.
Bernard TêtuCancer Research Centre, CHU de Québec, Québec, Canada. Bernard.Tetu@fmed.ulaval.ca.
Vincent FradetDepartment of Surgery/Urology, Faculty of Medicine, Laval University, Québec, Canada. vincent.fradet@fmed.ulaval.ca.
Université Laval · CACentre hospitalier universitaire de Québec · CAUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe tumor proliferative index marker Ki-67 was shown to be associated with clinically significant outcomes in prostate cancer, but its clinical application has limitations due to lack of uniformity and consistency in quantification. Our objective was to compare the measurements obtained with digital image analysis (DIA) versus virtual microscopy (visual scoring (VS)).

methodsTo do so, we compared the measurement distributions of each technique and their ability to predict clinically useful endpoints. A tissue microarray series from a cohort of 225 men who underwent radical prostatectomy was immunostained for Ki-67. The percentage of Ki-67 positive nuclei in malignant cells was assessed both by VS and DIA, and a H-score was calculated. The distribution and predictive ability of these scoring methods to predict biochemical recurrence (BCR) and death from prostate cancer (DPCa) were compared using Mann-Whitney test and C-index.

resultsThe measurements obtained with VS were similar to the DIA measurements (p = 0.73) but dissimilar to the H-score (p < 0.001). Cox regression models showed that Ki-67 was associated with BCR (HR 1.46, 95 % CI 1.10-1.94) and DPCa (HR 1.26, 95 % CI 1.06-1.50). C-indexes revealed that Ki-67 was a better predictor of DPCa (0.803, 0.8059 and 0.789; VS, DIA and H-score, respectively) than of BCR (0.625, 0.632 and 0.604; VS, DIA and H-score, respectively).

conclusionThe measurement distributions and the predictive abilities of VS and DIA were similar and presented the same predictive behaviour in our cohort, supporting the role of Ki-67 proliferative index as an important prognostic factor of BCR and DPCa in prostate cancer post RP. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/6656878501536663.

Indexed as

Cell ProliferationImage Interpretation, Computer-AssistedImmunohistochemistryProstatectomyAgedDisease-Free SurvivalHumansKi-67 AntigenMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsProportional Hazards ModelsProstatic NeoplasmsRecurrenceReproducibility of ResultsKi-67 Antigen

Identifiers

PMID26070608
PMCPMC4465166
OpenAlexW1800092462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.